[Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis]

C P Tilbery; M A Moreira; M F Mendes; M A Lana-Peixoto

doi:10.1590/s0004-282x2000000400030

[Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis]

Arq Neuropsiquiatr. 2000 Sep;58(3A):769-76. doi: 10.1590/s0004-282x2000000400030.

[Article in Portuguese]

Authors

C P Tilbery, M A Moreira, M F Mendes, M A Lana-Peixoto

PMID: 10973126
DOI: 10.1590/s0004-282x2000000400030

Abstract

After brief considerations about clinical course and diagnosis in multiple sclerosis, the members of the BCTRIMS present some recommendations for the use of the immunomodulatory drugs in the treatment of this disease.

Publication types

Consensus Development Conference
English Abstract
Review

MeSH terms

Adjuvants, Immunologic / therapeutic use*
Glatiramer Acetate
Humans
Interferon beta-1a
Interferon beta-1b
Interferon-beta / therapeutic use
Multiple Sclerosis / diagnosis
Multiple Sclerosis / drug therapy*
Peptides / therapeutic use
Severity of Illness Index

Substances

Adjuvants, Immunologic
Peptides
Interferon beta-1b
Glatiramer Acetate
Interferon-beta
Interferon beta-1a